In the latest trading session, Moderna (MRNA) closed at $148.59, marking a -1.6% move from the previous day.
Moderna said Monday its Covid/flu vaccine topped rivals from GSK and Sanofi, and its own Spikevax shot. But Moderna stock fell.
Moderna (MRNA) completes regulatory filing of its Spikevax 2024-2025 formula, targeting the COVID-19 variant JN.1 to the FDA for the upcoming vaccination season.